Cochlear implant provider awareness of vaccination guidelines

Jeyakumar, Anita; Bégué, Rodolpho E.; Jiang, Yu; McKinnon, Brian J.

doi:10.1002/lary.27117

Cited by 2 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the pneumococcal vaccination recommendations have been in effect for many years now, it is concerning how drastically variable the rates are from full compliance. 10 One explanation could be secondary to a lack of provider awareness. In 2018, the results of a survey of 256 providers revealed that knowledge of vaccination guidelines in patients undergoing cochlear implantation was high; however, understanding of age group-specific immunizations and recording of vaccinations into a database were both reported as low.…”

Section: Discussionmentioning

confidence: 99%

“…This notion of perceived mixed efficacy is considered to be a limiting factor in some providers prioritizing immunization. 10 To date, there are no human studies correlating pneumococcal vaccination and meningitis within the cochlear implant population cohort. 16 This will require an extended data collection period, given the already low incidence of meningitis.…”

Section: Discussionmentioning

confidence: 99%

“…Interestingly, in Poland, where this study took place, children are entitled to free vaccination if deemed high risk; however, adults of the same high‐risk status are not. In addition to variations in funding, providers have consistently reported challenges in PCV13 vaccination administration within the older child and adult population 10 . This is mainly due to inadequate knowledge of vaccination catch‐up schedules beyond the routine schedule in infancy 37 .…”

Section: Discussionmentioning

confidence: 99%

“…In 2018, the results of a survey of 256 providers revealed that knowledge of vaccination guidelines in patients undergoing cochlear implantation was high; however, understanding of age group-specific immunizations and recording of vaccinations into a database were both reported as low. 10 Furthermore, the data variability could also be attributed to differences in pneumococcal vaccination schedules between countries. Of the studies included in the analysis, Davidson et al 25 reported the lowest compliance rate for both PCV13 and PPSV23.…”

Section: Discussionmentioning

confidence: 99%

“…8 The most common causative agent of meningitis in patients receiving a CI is Streptococcus pneumoniae, followed by Haemophilus influenzae type B, and Neisseria meningitidis. 9,10 Due to the increased risk of pneumococcal meningitis, the Centers for Disease Control and Prevention (CDC) began recommending the 23-valent pneumococcal polysaccharide vaccination (PPSV23) in all patients over 2 years of age receiving a CI, beginning in 2002. This recommendation was validated by an animal study in 2007, confirming the protective effect of the PPSV23 vaccination against hematogenous and middle ear infections.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Improving Pneumococcal Vaccination Rates in Cochlear Implant Programs: A Systematic Review and Meta‐analysis

Britt

Poupore

Nguyen

et al. 2022

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective To review the literature on pneumococcal vaccination compliance rates among cochlear implant (CI) patients and to examine the utility of intervention programs on increasing vaccination rates. Data Sources PubMed, Scopus, and CINAHL. Review Methods A systematic review was performed following PRISMA guidelines. Studies of pneumococcal vaccination rates at baseline and before and after the implementation of a quality improvement (QI) intervention were included. A total of 641 studies were screened, and 13 studies met inclusion criteria. Meta-analyses of pneumococcal vaccination rates pre- and post-QI intervention in CI patients were performed. Results A total of 12,973 children and adults were included. The baseline PCV13 and PPSV23 vaccination rates were 53.45% (95% CI, 37.02%-69.51%) and 42.53% (95% CI, 31.94%-53.48%), respectively. Comparing children and adults, PCV13 and PPSV23 baseline vaccination rates were not statistically significant. The PPSV23 vaccine rate after QI initiatives was significantly higher than the baseline rate at 83.52% (95% CI, 57.36%-98.46%). After these interventions, patients had a 15.71 (95% CI, 4.32-57.20, P < .001) increased odds of receiving PPSV23 vaccination compared to before QI implementation. Conclusions The baseline rates of PCV13 and PPSV23 are highly variable and lower than expected, given current vaccination recommendations for CI patients. QI programs appear successful in increasing compliance rates with the PPSV23 vaccination; however, they are still far from full compliance. Further intervention programs with stricter surveillance, monitoring, and follow-up systems are needed to achieve improved compliance with the PCV13 and PPSV23 vaccination in CI recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%